Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

United Therapeutic (NQ: UTHR )

218.36 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 218.36
Bid (Size) 210.00 (1)
Ask (Size) 219.03 (2)
Prev. Close 218.36
Today's Range 218.36 - 218.36
52wk Range 158.38 - 245.48
Shares Outstanding 44,891,523
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
New Drugs in Pipeline for Hypertension, the Silent Global Pandemic
Via Investor Brand Network
Exposures Product Safety
United Therapeutics: Return On Capital Employed Overview
  
Via Benzinga

Performance

YTD
+3.67%
+3.67%
1 Month
-6.73%
-6.73%
3 Month
+17.95%
+17.95%
6 Month
+7.65%
+7.65%
1 Year
+9.47%
+9.47%

More News

Read More
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Via Benzinga
Expert Ratings for United Therapeutics
Via Benzinga
New Drugs in Pipeline for Hypertension, the Silent Global Pandemic
Via FinancialNewsMedia
Exposures Product Safety
United Therapeutics Corporation Reports Second Quarter 2022 Financial Results
From United Therapeutics Corporation
Via Business Wire
Earnings Outlook For United Therapeutics
Via Benzinga
Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review
Via Investor's Business Daily
United Therapeutics Corporation to Report Second Quarter 2022 Financial Results Before the Market Opens on Wednesday, August 3, 2022
From United Therapeutics Corporation
Via Business Wire
7 Best Pharmaceutical Stocks to Buy Now
Via InvestorPlace
Swing Trading Stock Watchlist For The Week Of July 11 And Beyond
Via Talk Markets
7 Biotech Stocks With Key Catalysts Coming in July
Via InvestorPlace
Buy These 3 Low-Beta Stocks To Sail Through A Choppy Market
Via Talk Markets
Corcept Stock Near Buy Point; Strength Rating Jumps To 91
Via Investor's Business Daily
Will Investors Notice Exciting Sign On United Therapeutics's Chart?
Via Benzinga
United Therapeutics Provides an Update on Its Organ Printing Programs
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Present at the Jefferies Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
Short Volatility Alert: United Therapeutics Corporation
Via Benzinga
United Therapeutics Stock Sees RS Rating Jump To 89; Earns 'Blue Dot'
Via Investor's Business Daily
The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures
Via Benzinga
United Therapeutics Announces FDA Approval of Tyvaso DPI™
From United Therapeutics Corporation
Via Business Wire
United Therapeutics's Return on Invested Capital Insights
Via Benzinga
7 Biotech Stocks With Key Catalysts for May
Via InvestorPlace
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Via Benzinga
Recap: United Therapeutics Q1 Earnings
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.